参考文献 (References)[1] C. Antonio, M. Enrico. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24: 816- 823.
[2] R. Gerald, A. Fahim and M. Tracey. Obesity, insulin resistance, and cardiovascular disease. Endocrine Reviews, 2004, 59(1): 207- 223.
[3] M. Claudia, T. Vincenzo and D. Alessandro. Genetic influences of adiponectin on insulin resistance, type2 diabetes, and cardiovascular disease. Diabetes, 2007, 56(5): 1198-1209.
[4] M. Reza, A. Khosrow. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clinical Biochemistry, 2009, 42(13-14): 1331-1346.
[5] E. Gunnar. Prevalence of cardiovascular risk factors and concentration of C-reactive protein in Type D personality persons without cardiovascular disease. European Journal of Preventive Cardiology, 2011, 18(3): 504-509.
[6] P. Mathieu, I. Lemieux and J. P. Després. Obesity, inflammation, and cardiovascular risk. Clinical Pharmacology & Therapeutics, 2010, 87(4): 407-416.
[7] Z. X. Wang, N. Tomohiro. Inflammation, a link between obesity and cardiovascular disease. Mediators of Inflammation, 2010, 2010: 17.
[8] M. Elena, C. S. Crowson, H. M. Kremers, V. L. Roger, P. D. Fitz-Gibbon, T. M. Therneau and S E. Gabrie. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Clinical and Epidemiological Research, 2011, 70(3): 482-487.
[9] T. Lisman, S. H. Caldwell, A. K. Burroughs, P. G. Northup, M. Senzolo, R. T. Stravitz, A. Tripodi, J. F. Trotter, D. C. Valla and R. J. Porte. Hemostasis and thrombosis in patients with liver disease: The ups and downs. Journal of Hepatology, 2010, 53(2): 362-371.
[10] E. Brodin, T. Vikan, J. B. Hansen and J. Svartberg. Testosterone, hemostasis, and cardiovascular diseases in men. Seminars in Thrombosis and Hemostasis, 2011, 37(1): 87-94.
[11] S. Yende, G. D’Angelo, F. Mayr, J. A. Kellum, L. Weissfeld, A. M. Kaynar, T. Young, K. Irani and D C. Angus. Elevated hemostasis markers after pneumonia increases one-year risk of all-cause and cardiovascular deaths. Hemostasis Markers and Pneumonia Mortality, 2011, 6(8): e22847.
[12] R. Pop-Busui, G. W. Evans, H. C. Gerstein, V. Fonseca, J. L. Fleg, B. J. Hoogwerf, S. Genuth, R. H. Grimm, M. A. Corson and R. Prineas. Effects of cardiac autonomic dysfunction on mortality risk in the action to control cardiovascular risk in diabetes (ACCORD) trial. Diabetes Care, 2010, 33(7): 1578-1584.
[13] P. Paolo, J. Stevo. The role of cardiac autonomic function in hypertension and cardiovascular disease. Current Hypertension Reports, 2007, 11(3): 199-205.
[14] X. Wang, X. Ding, S. Su, Z. Li, H. Riese, J. F. Thayer, et al. Genetic influences on heart rate variability at rest and during stress. Psychophysiology. 2009, 46(3): 458-465.
[15] N. Kupper, G. Willemsen, D. Posthuma, D. De Boer, D. Boomsma and E. J. De Geus. A genetic analysis of ambulatory cardiorespiratory coupling. Psychophysiology, 2005, 42(2): 202-212.
[16] N. Kupper, G. Willemsen, D. I. Boomsma and E. J. De Geus. Heritability of indices for cardiac contractility in ambulatory recordings. Journal of Cardiovascular Electrophysiology, 2006, 17(8): 877-883.
[17] Andrew, H, Kemp, Quintana D S, Gray M A. Is heart rate variability reduced in depression without cardiovascular disease? Biological Psychiatry, 2011, 69(4): e3-e4.
[18] A. C. Phillips. Blunted cardiovascular reactivity relates to depression, obesity, and self-reported health. Biological Psychology, 2011, 86(2): 106-113.
[19] A. J. Grippo, A. K. Johnson. Stress, depression and cardiovascular dysregulation: A review of neurobiological mechanisms and the integration of research from preclinical disease models. Stress, 2009, 12(1): 1-21.
[20] P. F. Sullivan, M. C. Neale and K. S. Kendler. Genetic epidemiology of major depression: Review and meta-analysis. American Journal of Psychiatry, 2000, 157(10): 1552-1562.
[21] A. M. Thompson, T. Hu, C. L. Eshelbrenner, K. Reynolds, J. He and L. A. Bazzano. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension. Journal of the American Medical Association, 2011, 305(9), 913-922.
[22] Buxtona, O M, Marcelli E. Short and long sleep are positively associated with obesity, diabetes, hypertension, and cardiovascular disease among adults in the United States. Social Science & Medicine, 2010, 71(5): 1027-1036.
[23] D. M. Mannino, D. Thorn, A. Swensen and F. Holguin. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. European Respiratory Journal, 2008, 32(4): 962-969.
[24] C. M. Champagne. Magnesium in hypertension, cardiovascular disease, metabolic syndrome, and other conditions: A review. Nutrition in Clinical Practice, 2008, 23(2): 142-151.
[25] A. G. Olsson. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease. Expert Opinion on Pharmacotherapy, 2010, 11(10): 1715-1726.
[26] M. J. Chapmana, J. S. Redfernc, M. E. McGovernd and P. Giral. Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacology & Therapeutics, 2010, 126(3): 314-345.
[27] J. Genest, et al. Canadian cardiovascular society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. Canadian Journal of Cardiology, 2009, 25(10): 567- 579.
[28] D. Maccubbin, et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. The American Journal of Cardiology, 2009, 104(1): 74-81.
[29] C. J. Lavie, R. V. Milani and H. O. Ventura. Obesity and cardiovascular disease: Risk factor, paradox, and impact of weight loss. Journal of the American College of Cardiology, 2009, 53(21): 1925-1932.
[30] S. S. Martin, A. Qasim and M. P. Reilly. Leptin resistance: A possible interface of inflammation and metabolism in obesity-related cardiovascular disease. Journal of the American College of Cardiology, 2008, 52(15): 1201-1210.
[31] G. M. Reaven. Insulin resistance: The link between obesity and cardiovascular disease. Medical Clinics of North America, 2011, 95(5): 875-892.
[32] 姚如珍. 人格特征与心身疾病[J]. 临床心身疾病杂志, 2006, 12(1).
[33] F. Mols, J. Denollet. Type D personality in the general population: A systematic review of health status, mechanisms of disease, and work-related problems. Mols and Denollet Health and Quality of Life Outcomes, 2010, 8: 9.
[34] N. Kupper, J. Denollet, E. J. De Geus, D. I. Boomsma and G. Willemsen. Heritability of type-D personality. Psychosomatic Medicine, 2007, 69(7): 675-681.
[35] 瞿云中,黄彦科, 姚树桥. D型人格量表用于心血管病人群的信效度[J]. 中国临床心理学杂志, 2009, 17(4): 452-456.
[36] 张勇, 张亚林, 邹韶红, 李恒芬. D型人格量表在儿童少年情绪障碍患者中的信度效度研究. 中国行为医学科学, 2006, 15(8): 757-759.
[37] T. W. Kamarck, W. R. Lovallo. Cardiovascular reactivity to psychological challenge: Conceptual and measurement considerations. Psychosomatic Medicine, 2003, 65(1): 9-21.
[38] A. Mathews, C. MacLeod. Cognitive approaches to emotion and emotional disorders. Annual Review of Psychology, 1994, 45(1): 25-50.
[39] A. Mathews, C. MacLeod. Cognitive vulnerability to emotional disorders. Annual Review of Clinical Psychology, 2005, 1: 167- 195.
[40] A. C. Puliafico, P. C. Kendall. Threat-related attentional bias in anxious youth: A review. Clinical Child and Family Psychology Review, 2006, 9(3): 162-180.
[41] T. Dalgleish, F. N. Watts. Biases of attention and memory in disorders of anxiety and depression. Clinical Psychology Review, 1990, 10(5): 589-604.
[42] L. Sharpe, B. F. Dear and L. Schrieber. Attentional biases in chronic pain associated with rheumatoid arthritis: Hypervigilance or difficulties disengaging? The Journal of Pain: Official Journal of the American Pain Society, 2009, 10(3): 329.
[43] E. Smeets, A. Roefs, E. Van Furth and A. Jansen. Attentional bias for body and food in eating disorders: Increased distraction, speeded detection, or both? Behaviour Research and Therapy, 2008, 46(2): 229-238.
[44] S. Hayes, C. R. Hirsch, G. Krebs and A. Mathews. The effects of modifying interpretation bias on worry in generalized anxiety disorder. Behaviour Research and Therapy, 2010, 48(3): 171- 178.
[45] C. MacLeod, E. Rutherford, L. Campbell, G. Ebsworthy and L. Holker. Selective attention and emotional vulnerability: Assessing the causal basis of their association through the experimental manipulation of attentional bias. Journal of Abnormal Psychology, 2002, 111(1): 107-123.
[46] A. M. Waters, J. S. Valvoi. Attentional bias for emotional faces in paediatric anxiety disorders: An investigation using the emotional go/no go task. Journal of Behavior Therapy and Experimental Psychiatry, 2009, 40(2): 306-316.
[47] Y. Bar-Haim, D. Lamy, L. Pergamin, M. J. Bakermans-Kranenburg and M. H. Van IJzendoorn. Threat-related attentional bias in anxious and nonanxious individuals: A meta-analytic study. Psychological Bulletin, 2007, 133(1): 1-24.
[48] J. M. Cisler, E. H. W. Koster. Mechanisms of attentional biases towards threat in the anxiety disorders: An integrative review. Clinical Psychology Review, 2010, 30(2): 203-216.